Pharmaceutical

SNK-396 by Synerk for Lipid Disorders: Likelihood of Approval

SNK-396is under clinical development by Synerk and currently in Phase I for Lipid Disorders.

Jul 1, 2023 - 20:00
SNK-396is under clinical development by Synerk and currently in Phase I for Lipid Disorders.
Read the original article

Tags:

Previous Article

IN-14199 by HK inno.N for Constipation: Likelihood of Approval

Next Article

Immune Thrombocytopenia by NovelMed Therapeutics for Idiopathic Thrombocytopenic...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FTC warns drugmakers they can face legal action over improper patent listings

STAT+: FTC warns drugmakers they can face legal action ...

Sep 14, 2023

Vaccine experts urge more inclusivity in clinical trials

Vaccine experts urge more inclusivity in clinical trials

Sep 6, 2023

Over 20,000 UK businesses at risk of Chinese espionage, warns MI5 chief

Over 20,000 UK businesses at risk of Chinese espionage,...

Oct 21, 2023